Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

Completed · Phase 3

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the levels of antibodies 1 year after receiving the second vaccine dose in two groups of adults over the age of 60: (1) those who have previously received 2 doses of 13-valent pneumococcal conjugate vaccine (13vPnC) and (2) those who have previously received 1 dose of 13vPnc and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS). This study will also assess whether the use of the 2 vaccines, 13vPnC and 23vPS, administered in different sequential order results in different prolonged antibody levels. This study is limited to individuals who participated in either study 6115A1-3010 (NCT00574548) or 6115A1-3005 (NCT00546572).

Key facts

Study ID

NCT01025336

Run by

Pfizer

People needed

962

Starts

2009-12-01

Expected to finish

2010-10-01

Last updated by the study team

2012-06-20

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Only study volunteers who received both assigned vaccinations at visit 1 and visit 4 when they participated in either study 6115A1-3010 (NCT00574548) or 6115A1-3005 (NCT00546572)

You may not qualify if…

• Vaccination with any licensed or experimental pneumococcal vaccine since being enrolled in the 6115A1-3005 (NCT00546572) or 6115A1-3010 (NCT00574548) study (other than study vaccines permitted in 6115A1-3010 or 6115A1-3005)

Where it is running

• Pfizer Investigational Site — Chandler, Arizona, United States
• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Pinellas Park, Florida, United States
• Pfizer Investigational Site — Meridian, Idaho, United States
• Pfizer Investigational Site — Wichita, Kansas, United States
• Pfizer Investigational Site — Lexington, Kentucky, United States
• Pfizer Investigational Site — Kansas City, Missouri, United States
• Pfizer Investigational Site — St Louis, Missouri, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — Cary, North Carolina, United States
• Pfizer Investigational Site — Durham, North Carolina, United States
• Pfizer Investigational Site — Raleigh, North Carolina, United States
• Pfizer Investigational Site — Raleigh, North Carolina, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Cleveland, Ohio, United States
• Pfizer Investigational Site — Corvallis, Oregon, United States
• Pfizer Investigational Site — Eugene, Oregon, United States
• Pfizer Investigational Site — Carnegie, Pennsylvania, United States
• Pfizer Investigational Site — Grove City, Pennsylvania, United States
• Pfizer Investigational Site — Jefferson, Pennsylvania, United States
• Pfizer Investigational Site — Penndel, Pennsylvania, United States
• Pfizer Investigational Site — Pittsburgh, Pennsylvania, United States
• Pfizer Investigational Site — Greer, South Carolina, United States
• Pfizer Investigational Site — Mt. Pleasant, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.